Bitterman Kevin sold $3.4M of IRON (indirect holdings)
Bitterman Kevin sold 41,825 indirectly-held shares of Disc Medicine, Inc. (IRON) at an average of $80.13 ($79.95–$80.23, $3.35M total) across 9 trades over 2026-10-19 to 2026-10-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh, material information about insider sentiment, offering a modest trading signal.
Market read
The filing is a primary source of insider activity, offering a low‑to‑moderate trading insight for IRON.
What to watch
Potential upcoming clinical data releases or partnership news could offset any negative sentiment from the sale.
Background
Form 4 filings disclose insider transactions; a director's sale via a pre‑arranged 10b5‑1 plan is a standard reporting requirement.
Ticker impact
Director Kevin Bitterman sold 41,825 shares for $3.35M via a 10b5‑1 plan, reducing his stake to 12,991 shares.
likely pressure as investors digest the director's sale
A $3.35M sale by a director is material enough to attract attention but is not large enough to drive a significant move; typical market reaction is slight downside.
Market effects
Minimal impact on the broader biotech sector; insider sales are common and usually isolated.
No regional effect; the filing is specific to Disc Medicine.
Low; the transaction does not affect global markets.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals, so price may remain stable.
Key entities
- CompanyDisc Medicine, Inc.
Biotech firm focused on novel therapeutics.
- IndividualKevin Bitterman
Director of Disc Medicine who executed the sale.